Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Key Highlights
- ➤Entrada Therapeutics (TRDA) appoints Linea Aspesi as Chief People Officer
- ➤Aspesi brings more than twenty years of biopharmaceutical and technology experience
- ➤Aspesi previously served as Chief People Officer at KalVista Pharmaceuticals
- ➤Entrada’s lead oligonucleotide programs target Duchenne muscular dystrophy exon skipping
- ➤Entrada partners on clinical-stage VX-670 program for myotonic dystrophy type 1
Expert Statements
Dipal Doshi, Chief Executive Officer at Entrada Therapeutics
“Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages”
Dipal Doshi, Chief Executive Officer at Entrada Therapeutics
“We are in a catalyst-rich period with our neuromuscular programs, and Linea brings deep experience that will be invaluable as we continue to build an industry-leading culture that enables Entradans to do their best work and deliver on the potential of our pipeline. People are the foundation of any organization, and at Entrada, we know that a strong and engaged team is critical to our ability to develop a new class of genetic medicines and ultimately bring them to the patients who need them most.”
Linea Aspesi, Chief People Officer at Entrada Therapeutics
“Entrada is a company with a clear and steady commitment to patients and to one another”
Linea Aspesi, Chief People Officer at Entrada Therapeutics
“I’m thrilled to join the team at such an important time in Entrada’s growth and look forward to building on its strong, mission-driven culture and fostering an environment where our colleagues can continue to do their best work as we grow and advance our pipeline for patients.”
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer.
“Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “We are in a catalyst-rich period with our neuromuscular programs, and Linea brings deep experience that will be invaluable as we continue to build an industry-leading culture that enables Entradans to do their best work and deliver on the potential of our pipeline. People are the foundation of any organization, and at Entrada, we know that a strong and engaged team is critical to our ability to develop a new class of genetic medicines and ultimately bring them to the patients who need them most.”
Get started
Create a free account to read the full story.